| 货号 | AF2545-SP |
| 别名 | Placental protein 5; PP5; PP5FLJ21164; REF-1; TFPI-2REF1; tissue factor pathway inhibitor 2 | 全称 | Tissue Factor Pathway Inhibitor 2 |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) Immunoprecipitation(25 µg/mL) |
| 目标/特异性 | Detects human TFPI‑2 in direct ELISAs and Western blots. In direct ELISAs, approximately 10% cross‑reactivity with recombinant mouse TFPI-2 is observed and less than 5% cross‑reactivity with recombinant human TFPI‑1 is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Immunoprecipitation: 25 µg/mL Neutralization: Measured by its ability to neutralize Recombinant Human TFPI-2 (0.17 µg/mL, Catalog # 2545-PI) inhibition of Trypsin (0.05 µg/mL) cleavage of the fluorogenic peptide substrate Mca-RPKPVE-Nval-WRK(Dnp)-NH2 (10 µM, Catalog # ES002). The Neutralization Dose (ND50) is typically 1.4 µg/mL. |
| 来源 | Polyclonal Goat IgG |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 7980 (Human) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Use of an immunoaffinity-mass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients. | |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant human TFPI-2 Asp23-Lys213 Accession # P48307 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | Human Tissue Factor Pathway Inhibitor 2 (TFPI-2), also known as placental protein 5 (PP5) and retinal pigment epithelial cell factor 1 (REF-1), is a secreted protein with a N-terminal acidic region, three Kunitz (K) domains (residues 36 to 86, 96 to 149 and 158 to 208) separated with by two linker regions, and a C-terminal basic region (1‑3). Expression of TFPI-2 is down-regulated in several cancers, which may contribute to tumor progression in these cancers (4). The purified recombinant human TFPI-2 ends at residue 213 and does not contain the last 22 residues (residues 214 to 235) in the C-terminal region. It inhibits the activity of recombinant human Coagulation Factor VII (R&D Systems, Catalog # 2338-SE) in the presence of recombinant human Tissue Factor (R&D Systems, Catalog # 2339-PA). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|